Activity of novel β-lactam/β-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa
Su Young Lee,Christian M Gill,David P Nicolau,Elif Aktas,Wadha Alfouzan,Lori Bourassa,Adrian Brink,Carey-Ann D Burnham,Rafael Canton,Yehuda Carmeli,Marco Falcone,Carlos Kiffer,Anna Marchese,Octavio Martinez,Spyros Pournaras,Michael Satlin,Harald Seifert,Abrar K Thabit,Kenneth S Thomson,Maria Virginia Villegas,Julia Wille,Thais Teles Freitas Rezende,Zuhal Cekin,Gulsah Malkocoglu,Desirae Gijón,Layla Abdullah Tarakmeh,Chun Yat Chu,Christoffel Johannes Opperman,Hafsah Deepa Tootla,Clinton Moodley,Jennifer Coetzee,Sophia Vourli,George Dimopoulos,Dalya M Attallah,Giusy Tiseo,Alessandro Leonildi,Cesira Giordano,Simona Barnini,Francesco Menichetti,Vincenzo Di Pilato,Giulia Codda,Antonio Vena,Daniele Roberto Giacobbe,Lars Westblade,Armando Cardona,Lauren Curtis,Ferric Fang,Gina Thomson,
DOI: https://doi.org/10.1093/jac/dkad225
2023-10-16
Journal of Antimicrobial Chemotherapy
Abstract:Abstract Background Antimicrobial resistance in Pseudomonas aeruginosa is complex and multifaceted. While the novel β-lactamase inhibitors (BLIs) avibactam, relebactam and vaborbactam inhibit serine-based β-lactamases, the comparative potency of the novel β-lactam (BL)/BLI combinations against serine carbapenemase-producing P. aeruginosa is unknown. Objectives To compare the in vitro activity of ceftazidime/avibactam, ceftazidime, imipenem/relebactam, imipenem, meropenem/vaborbactam and meropenem against serine β-lactamase-producing P. aeruginosa. Methods Carbapenem-resistant P. aeruginosa were collated through the Enhancing Rational Antimicrobials against Carbapenem-resistant P. aeruginosa (ERACE-PA) Global Surveillance. Isolates positive for serine-based carbapenemases were assessed. MICs were determined by broth microdilution to each novel BL/BLI and BL alone. Results GES was the most common carbapenemase identified (n = 59) followed by KPC (n = 8). Ceftazidime/avibactam had MIC50/MIC90 values of 4/8 mg/L and 91% of isolates were susceptible. Conversely, ceftazidime alone was active against only 3% of isolates. The MIC50/MIC90 of imipenem/relebactam were 16/>16 mg/L and 13% of all isolates were defined as susceptible. Of the KPC-producing isolates, 38% were susceptible to imipenem/relebactam, compared with 0% to imipenem. The meropenem/vaborbactam MIC50/MIC90 were >16/>16 mg/L, and 6% of isolates were susceptible, which was similar to meropenem alone (MIC50/90, >8/>8 mg/L; 3% susceptible) suggesting the addition of vaborbactam cannot overcome co-expressed, non-enzymatic resistance mechanisms. Conclusions Among the novel BL/BLIs, ceftazidime/avibactam displayed better in vitro activity and thus is a rational treatment option for serine carbapenemase-harbouring P. aeruginosa. While imipenem/relebactam displayed some activity, particularly against isolates with blaKPC, meropenem/vaborbactam exhibited poor activity, with MICs similar to meropenem alone.
pharmacology & pharmacy,infectious diseases,microbiology